JP7523883B2 - 分子ｍｒイメージング用マンガン系キレートコンジュゲート - Google Patents

分子ｍｒイメージング用マンガン系キレートコンジュゲート Download PDF

Info

Publication number
JP7523883B2
JP7523883B2 JP2018506981A JP2018506981A JP7523883B2 JP 7523883 B2 JP7523883 B2 JP 7523883B2 JP 2018506981 A JP2018506981 A JP 2018506981A JP 2018506981 A JP2018506981 A JP 2018506981A JP 7523883 B2 JP7523883 B2 JP 7523883B2
Authority
JP
Japan
Prior art keywords
alkyl
tbm
iii
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018506981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523671A (ja
JP2018523671A5 (https=
Inventor
エム． ゲール，エリック
キャラヴァン，ピーター
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2018523671A publication Critical patent/JP2018523671A/ja
Publication of JP2018523671A5 publication Critical patent/JP2018523671A5/ja
Priority to JP2021165864A priority Critical patent/JP7482099B2/ja
Priority to JP2023192615A priority patent/JP2024026077A/ja
Application granted granted Critical
Publication of JP7523883B2 publication Critical patent/JP7523883B2/ja
Priority to JP2025194871A priority patent/JP2026048654A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/143—Peptides, e.g. proteins the protein being an albumin, e.g. HSA, BSA, ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/76—Metal complexes of amino carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/57—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton
    • C07C309/61—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing carboxyl groups bound to the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/86—Hydrazides; Thio or imino analogues thereof
    • C07D213/87—Hydrazides; Thio or imino analogues thereof in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicinal Preparation (AREA)
JP2018506981A 2015-08-13 2016-08-12 分子ｍｒイメージング用マンガン系キレートコンジュゲート Active JP7523883B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021165864A JP7482099B2 (ja) 2015-08-13 2021-10-08 分子ｍｒイメージング用マンガン系キレートコンジュゲート
JP2023192615A JP2024026077A (ja) 2015-08-13 2023-11-10 分子ｍｒイメージング用マンガン系キレートコンジュゲート
JP2025194871A JP2026048654A (ja) 2015-08-13 2025-11-14 分子ｍｒイメージング用マンガン系キレートコンジュゲート

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562204519P 2015-08-13 2015-08-13
US62/204,519 2015-08-13
US201662356732P 2016-06-30 2016-06-30
US62/356,732 2016-06-30
PCT/US2016/046874 WO2017027834A1 (en) 2015-08-13 2016-08-12 Manganese-based chelate conjugates for molecular mr imaging

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2021165864A Division JP7482099B2 (ja) 2015-08-13 2021-10-08 分子ｍｒイメージング用マンガン系キレートコンジュゲート
JP2023192615A Division JP2024026077A (ja) 2015-08-13 2023-11-10 分子ｍｒイメージング用マンガン系キレートコンジュゲート

Publications (3)

Publication Number Publication Date
JP2018523671A JP2018523671A (ja) 2018-08-23
JP2018523671A5 JP2018523671A5 (https=) 2019-09-19
JP7523883B2 true JP7523883B2 (ja) 2024-07-29

Family

ID=57984258

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018506981A Active JP7523883B2 (ja) 2015-08-13 2016-08-12 分子ｍｒイメージング用マンガン系キレートコンジュゲート
JP2021165864A Active JP7482099B2 (ja) 2015-08-13 2021-10-08 分子ｍｒイメージング用マンガン系キレートコンジュゲート
JP2023192615A Pending JP2024026077A (ja) 2015-08-13 2023-11-10 分子ｍｒイメージング用マンガン系キレートコンジュゲート
JP2025194871A Pending JP2026048654A (ja) 2015-08-13 2025-11-14 分子ｍｒイメージング用マンガン系キレートコンジュゲート

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021165864A Active JP7482099B2 (ja) 2015-08-13 2021-10-08 分子ｍｒイメージング用マンガン系キレートコンジュゲート
JP2023192615A Pending JP2024026077A (ja) 2015-08-13 2023-11-10 分子ｍｒイメージング用マンガン系キレートコンジュゲート
JP2025194871A Pending JP2026048654A (ja) 2015-08-13 2025-11-14 分子ｍｒイメージング用マンガン系キレートコンジュゲート

Country Status (6)

Country Link
US (2) US10835623B2 (https=)
EP (1) EP3334464B1 (https=)
JP (4) JP7523883B2 (https=)
CN (3) CN114890941A (https=)
ES (1) ES2987778T3 (https=)
WO (1) WO2017027834A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017027834A1 (en) * 2015-08-13 2017-02-16 The General Hospital Corporation Manganese-based chelate conjugates for molecular mr imaging
CN108888781B (zh) * 2018-06-27 2021-08-06 华东理工大学 一种超分子聚电解质胶束磁共振成像造影剂的制备方法
US11267832B2 (en) 2018-10-22 2022-03-08 The Board Of Regents Of The University Of Texas System Mn(II)-based sensors to detect zinc in vivo with MRI
CN112540095B (zh) * 2019-09-20 2022-03-22 华中农业大学 酶促低场核磁共振免疫传感器检测食源性致病菌的方法
AU2020404988A1 (en) * 2019-12-17 2022-05-26 The General Hospital Corporation Highly efficient myeloperoxidase activatable imaging agents
CN113248422B (zh) * 2020-02-10 2022-07-12 河南工业大学 一种手性α-氮杂芳烃四级碳中心类化合物、其制备方法及应用
WO2022108919A1 (en) * 2020-11-17 2022-05-27 The General Hospital Corporation Probes, systems, and methods for magnetic resonance ph sensing
US12180328B2 (en) 2021-05-04 2024-12-31 Sachem, Inc. Strong binding metal-chelating resins
TW202308755A (zh) 2021-05-04 2023-03-01 美商沙坎公司 使用大環分子的強結合金屬螯合樹脂
WO2024086331A1 (en) * 2022-10-21 2024-04-25 The General Hospital Corporation Iron based mri probes
CN119499407B (zh) * 2024-11-25 2026-04-07 中国科学院精密测量科学与技术创新研究院 一种Fe基T7肽靶向脑胶质瘤小分子磁共振造影剂及其制备合成方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525282A (ja) 2000-03-02 2003-08-26 マリンクロッド・インコーポレイテッド 診断および治療用の新規キノリン配位子および金属錯体
WO2014044916A1 (en) 2012-09-24 2014-03-27 Qi Wang Chelates, chelating agents, conjugates derived thereof and their use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
US4880008A (en) 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4889931A (en) 1988-09-27 1989-12-26 Salutar, Inc. Manganese (II) chelate manufacture
JP2772875B2 (ja) 1991-05-14 1998-07-09 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料の処理方法及び写真用漂白定着組成物
WO1994001406A1 (de) * 1992-07-01 1994-01-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Kontrastmittel für die mr diagnostik
DE69502796T2 (de) * 1994-10-20 1998-10-01 Fuji Photo Film Co Ltd Neuer Eisen-Komplex, Verfahren zu seiner Herstellung, photographische Verarbeitungslösung und photographisches Verarbeitungsverfahren unter Verwendung dieses Komplexes
JP3437013B2 (ja) * 1994-10-20 2003-08-18 富士写真フイルム株式会社 新規な鉄錯体、その製造方法、写真用処理組成物およびその処理方法
TW319763B (https=) 1995-02-01 1997-11-11 Epix Medical Inc
DE19603033A1 (de) 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
WO1997048787A1 (en) 1996-06-19 1997-12-24 Unilever N.V. Bleach activation
US6515113B2 (en) 1999-02-18 2003-02-04 The Regents Of The University Of California Phthalamide lanthanide complexes for use as luminescent markers
WO2000048991A1 (en) 1999-02-18 2000-08-24 The Regents Of The University Of California Salicylamide-lanthanide complexes for use as luminescent markers
DE60021545T2 (de) * 1999-04-01 2006-03-02 Unilever N.V. Zusammensetzung und verfahren zum bleichen eines substrats
TWI290146B (en) 1999-07-29 2007-11-21 Dyax Corp Binding moieties for fibrin
BR0013171A (pt) 1999-07-29 2002-05-28 Epix Medical Inc Agentes multimericos para formação de imagem de objetivação através de ligação multi-local
US6984373B2 (en) 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
US6549798B2 (en) 2001-02-07 2003-04-15 Epix Medical, Inc. Magnetic resonance angiography data
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
US6869591B2 (en) 2002-03-26 2005-03-22 Barnes-Jewish Hospital Paramagnetic particles that provide improved relaxivity
FR2856689A1 (fr) 2003-06-25 2004-12-31 Guerbet Sa Composes specifiques a forte relaxivite
FR2890657B1 (fr) * 2005-09-15 2007-11-09 Commissariat Energie Atomique Procede d'obtention de complexes de lanthanides hautement luminescents.
US20080058636A1 (en) 2005-12-29 2008-03-06 Epix Pharmaceuticals, Inc. Methods of myocardial imaging
WO2008073458A2 (en) 2006-12-11 2008-06-19 Bracco Imaging S.P.A. Fibrin-binding peptides and conjugates thereof
DE112010004188T5 (de) * 2009-10-28 2012-11-22 Sumitomo Chemical Co., Ltd. Metallkomplex mit mehrzähnigem Liganden
JP5856982B2 (ja) * 2010-02-19 2016-02-10 ノルディオン （カナダ） インク．Ｎｏｒｄｉｏｎ（Ｃａｎａｄａ）Ｉｎｃ． 二官能性キレート化剤
HUE054111T2 (hu) 2013-01-07 2021-08-30 Massachusetts Gen Hospital Mangán-bázisú mágneses rezonancia kontrasztanyagok
US20140350256A1 (en) * 2013-05-21 2014-11-27 University Of Southern Denmark Iron and manganese complexes comprising hexadentate monocarboxylato-containing ligands and their use for the catalysis of oxidation reactions
WO2015085005A1 (en) * 2013-12-03 2015-06-11 The General Hospital Corporation Molecular imaging probes
AR104939A1 (es) * 2015-06-10 2017-08-23 Chemsenti Ltd Método oxidativo para generar dióxido de cloro
US10233205B2 (en) * 2015-08-07 2019-03-19 Auburn University Magnetic resonance imaging contrast agent capable of detecting hydrogen peroxide and reducing reactive oxygen species
WO2017027834A1 (en) * 2015-08-13 2017-02-16 The General Hospital Corporation Manganese-based chelate conjugates for molecular mr imaging

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525282A (ja) 2000-03-02 2003-08-26 マリンクロッド・インコーポレイテッド 診断および治療用の新規キノリン配位子および金属錯体
WO2014044916A1 (en) 2012-09-24 2014-03-27 Qi Wang Chelates, chelating agents, conjugates derived thereof and their use

Also Published As

Publication number Publication date
EP3334464A1 (en) 2018-06-20
ES2987778T3 (es) 2024-11-18
CN114805196A (zh) 2022-07-29
JP7482099B2 (ja) 2024-05-13
JP2018523671A (ja) 2018-08-23
US11400171B2 (en) 2022-08-02
CA2995210A1 (en) 2017-02-16
US20190001003A1 (en) 2019-01-03
HK1253745A1 (zh) 2019-06-28
CN108136053A (zh) 2018-06-08
US10835623B2 (en) 2020-11-17
HK1257089A1 (en) 2019-10-11
WO2017027834A1 (en) 2017-02-16
CN114890941A (zh) 2022-08-12
EP3334464A4 (en) 2019-01-16
JP2026048654A (ja) 2026-03-17
EP3334464B1 (en) 2024-04-10
CN108136053B (zh) 2022-05-27
US20210015948A1 (en) 2021-01-21
JP2022017285A (ja) 2022-01-25
JP2024026077A (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
JP7482099B2 (ja) 分子ｍｒイメージング用マンガン系キレートコンジュゲート
MXPA02001017A (es) Agente multimerico de formacion de imagenes con especificidad hacia el blanco mediante su union a multiples regiones.
RU2561718C2 (ru) Хелаты марганца и их применение в качестве контрастных агентов в магнитно-резонансной визуализации (mpb)
KR101469900B1 (ko) Do3a-디아미노바이페닐 화합물 및 이를 리간드로 포함하는 가돌리늄 착물
JP2002220348A (ja) 肝臓胆管のｎｍｒコントラスト剤
Tripepi et al. Synthesis of high relaxivity gadolinium AAZTA tetramers as building blocks for bioconjugation
JP2020520998A (ja) 鉄（ｉｉｉ）ｍｒｉ造影剤として使用するための化合物
Yang et al. An intravascular MRI contrast agent based on Gd (DO3A-Lys) for tumor angiography
US20150297761A1 (en) Peptidic structures incorporating an amino acid metal complex and applications in magnetic resonance imaging
US20240285808A1 (en) Molecular probes for in vivo detection of aldehydes
HK40072595A (en) Manganese-based chelate conjugates for molecular mr imaging
HK40078341A (en) Manganese-based chelate conjugates for molecular mr imaging
CA2995210C (en) Manganese-based chelate conjugates for molecular mr imaging
CN112189014B (zh) 具有开关核磁共振造影增强的膀胱癌光动力治疗剂
WO2006121889A2 (en) Chemical exchange saturation transfer contrast agents
HK1253745B (en) Manganese-based chelate conjugates for molecular mr imaging
HK1257089B (en) Manganese-based chelate conjugates for molecular mr imaging

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190809

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200721

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211008

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211008

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211019

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211119

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211124

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220128

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220201

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221108

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240717

R150 Certificate of patent or registration of utility model

Ref document number: 7523883

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150